RU2020128276A - МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ - Google Patents
МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ Download PDFInfo
- Publication number
- RU2020128276A RU2020128276A RU2020128276A RU2020128276A RU2020128276A RU 2020128276 A RU2020128276 A RU 2020128276A RU 2020128276 A RU2020128276 A RU 2020128276A RU 2020128276 A RU2020128276 A RU 2020128276A RU 2020128276 A RU2020128276 A RU 2020128276A
- Authority
- RU
- Russia
- Prior art keywords
- group
- streptococcus
- modified lysine
- lysine polypeptide
- amino acid
- Prior art date
Links
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 37
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 102220232846 rs1085307645 Human genes 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 235000001014 amino acid Nutrition 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 16
- 238000000034 method Methods 0.000 claims 12
- 241000192125 Firmicutes Species 0.000 claims 9
- 230000003115 biocidal effect Effects 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 6
- 241000191967 Staphylococcus aureus Species 0.000 claims 6
- 241000894007 species Species 0.000 claims 6
- 241000194017 Streptococcus Species 0.000 claims 5
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 4
- 241000191940 Staphylococcus Species 0.000 claims 4
- 102220499972 Target of EGR1 protein 1_R35E_mutation Human genes 0.000 claims 4
- 108010059993 Vancomycin Proteins 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 229960003085 meticillin Drugs 0.000 claims 4
- 229960003165 vancomycin Drugs 0.000 claims 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 4
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 3
- 108010013198 Daptomycin Proteins 0.000 claims 3
- 241000186779 Listeria monocytogenes Species 0.000 claims 3
- 108090000988 Lysostaphin Proteins 0.000 claims 3
- 241000193985 Streptococcus agalactiae Species 0.000 claims 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims 3
- 229960005484 daptomycin Drugs 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 229960003128 mupirocin Drugs 0.000 claims 3
- 229930187697 mupirocin Natural products 0.000 claims 3
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000194032 Enterococcus faecalis Species 0.000 claims 2
- 241000194031 Enterococcus faecium Species 0.000 claims 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 2
- 241000191982 Staphylococcus hyicus Species 0.000 claims 2
- 241000191980 Staphylococcus intermedius Species 0.000 claims 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims 2
- 241000192097 Staphylococcus sciuri Species 0.000 claims 2
- 241000191978 Staphylococcus simulans Species 0.000 claims 2
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims 2
- 241000194049 Streptococcus equinus Species 0.000 claims 2
- 241001134658 Streptococcus mitis Species 0.000 claims 2
- 241000194019 Streptococcus mutans Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 241000194024 Streptococcus salivarius Species 0.000 claims 2
- 241000194023 Streptococcus sanguinis Species 0.000 claims 2
- 241000194021 Streptococcus suis Species 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 229940032049 enterococcus faecalis Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229940037648 staphylococcus simulans Drugs 0.000 claims 2
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 102000004092 Amidohydrolases Human genes 0.000 claims 1
- 108090000531 Amidohydrolases Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24075—Lysostaphin (3.4.24.75)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635515P | 2018-02-26 | 2018-02-26 | |
| US62/635,515 | 2018-02-26 | ||
| PCT/US2019/019638 WO2019165454A1 (en) | 2018-02-26 | 2019-02-26 | Modified plyss2 lysins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020128276A true RU2020128276A (ru) | 2022-03-29 |
Family
ID=67687985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020128276A RU2020128276A (ru) | 2018-02-26 | 2019-02-26 | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210032294A1 (https=) |
| EP (1) | EP3758738A4 (https=) |
| JP (1) | JP2021513865A (https=) |
| KR (1) | KR20200124724A (https=) |
| CN (1) | CN112118861A (https=) |
| AU (1) | AU2019224160A1 (https=) |
| BR (1) | BR112020017219A2 (https=) |
| CA (1) | CA3092109A1 (https=) |
| IL (1) | IL276807A (https=) |
| MX (1) | MX2020008860A (https=) |
| RU (1) | RU2020128276A (https=) |
| WO (1) | WO2019165454A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210691A1 (en) * | 2019-04-11 | 2020-10-15 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
| US20230277632A1 (en) * | 2020-05-19 | 2023-09-07 | Contrafect Corporation | MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA |
| WO2023049747A1 (en) * | 2021-09-22 | 2023-03-30 | Elanco Us Inc. | Streptococcus suis lytic enzyme compositions and methods of use thereof |
| WO2023081691A1 (en) * | 2021-11-04 | 2023-05-11 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
| CN115851689A (zh) * | 2022-08-09 | 2023-03-28 | 中南民族大学 | 一种嵌合裂解酶PlySs2E-V12C及其应用、重组质粒和重组菌株 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2699253T3 (en) * | 2011-04-21 | 2018-07-16 | Univ Rockefeller | STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES |
| DK3085777T3 (da) * | 2011-05-04 | 2020-02-03 | Micreos Human Health Bv | Polypeptid |
| RU2018121290A (ru) * | 2012-05-09 | 2019-03-06 | Контрафект Корпорейшн | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий |
| BR112014027818B1 (pt) * | 2012-05-09 | 2023-03-28 | Contrafect Corporation | Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano |
| CN104073478A (zh) * | 2014-06-13 | 2014-10-01 | 上海交通大学 | 杀灭革兰氏阳性菌的酶抗生素及其制备、用途 |
| CN104211781A (zh) * | 2014-09-04 | 2014-12-17 | 北京纳百景弈生物科技有限公司 | 金黄色葡萄球菌裂解蛋白的制备方法及其应用 |
| EP3454888B1 (en) * | 2016-05-12 | 2021-02-24 | Contrafect Corporation | Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides |
-
2019
- 2019-02-26 BR BR112020017219-7A patent/BR112020017219A2/pt not_active IP Right Cessation
- 2019-02-26 US US16/975,321 patent/US20210032294A1/en not_active Abandoned
- 2019-02-26 AU AU2019224160A patent/AU2019224160A1/en not_active Abandoned
- 2019-02-26 MX MX2020008860A patent/MX2020008860A/es unknown
- 2019-02-26 EP EP19757130.0A patent/EP3758738A4/en active Pending
- 2019-02-26 CA CA3092109A patent/CA3092109A1/en active Pending
- 2019-02-26 WO PCT/US2019/019638 patent/WO2019165454A1/en not_active Ceased
- 2019-02-26 CN CN201980027962.7A patent/CN112118861A/zh active Pending
- 2019-02-26 RU RU2020128276A patent/RU2020128276A/ru unknown
- 2019-02-26 JP JP2020544642A patent/JP2021513865A/ja active Pending
- 2019-02-26 KR KR1020207027681A patent/KR20200124724A/ko not_active Ceased
-
2020
- 2020-08-19 IL IL276807A patent/IL276807A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210032294A1 (en) | 2021-02-04 |
| CA3092109A1 (en) | 2019-08-29 |
| IL276807A (en) | 2020-10-29 |
| KR20200124724A (ko) | 2020-11-03 |
| EP3758738A1 (en) | 2021-01-06 |
| CN112118861A (zh) | 2020-12-22 |
| JP2021513865A (ja) | 2021-06-03 |
| AU2019224160A1 (en) | 2020-09-10 |
| EP3758738A4 (en) | 2021-12-08 |
| WO2019165454A1 (en) | 2019-08-29 |
| MX2020008860A (es) | 2020-12-10 |
| BR112020017219A2 (pt) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020128276A (ru) | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| JP7348255B2 (ja) | 抗菌療法 | |
| Al Atya et al. | Anti-MRSA activities of enterocins DD28 and DD93 and evidences on their role in the inhibition of biofilm formation | |
| Naber | Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies | |
| JP2021513865A5 (https=) | ||
| IL277119B2 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| Fan et al. | Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria | |
| EP3164146B1 (en) | Acinetobacter lysins | |
| JP2021506769A5 (https=) | ||
| WO2016142445A2 (en) | A method of treatment of a bacterial infection | |
| MX2014013587A (es) | Prevención, interrupción y tratamiento de biopelículas con lisina de bacteriófago. | |
| JPWO2019191633A5 (https=) | ||
| EP4138883B1 (en) | A chimeric endolysin polypeptide | |
| MX2021015563A (es) | Polipéptidos anti-microbianos, derivados de bacteriófago, y sus usos contra bacterias gramnegativas y acidorresistentes. | |
| JP2017533177A5 (https=) | ||
| Magana et al. | Therapeutic options and emerging alternatives for multidrug resistant staphylococcal infections | |
| WO2024153585A1 (en) | Selective caspase-8 inhibitors and uses thereof in augmenting innate immune defenses | |
| JPWO2019165454A5 (https=) | ||
| RU2771493C1 (ru) | Пептид, обладающий антибактериальной активностью в отношении микроорганизмов с множественной лекарственной устойчивостью | |
| Assar | Emergence of resistance to last-resort antibiotics in clinical isolates of staphylococci with special reference to daptomycin and linezolid | |
| US20220160842A1 (en) | Method of treating infective endocarditis | |
| JP2021522336A (ja) | フィブリノーゲンガンマプライム変種の治療的使用 | |
| JPWO2019191598A5 (https=) | ||
| US20230416719A1 (en) | Engineered chimeric antimicrobial agents against gram-positive bacteria |